EZH2在泛癌中的表达特征、预后价值及其与肝癌免疫微环境的关系
Expression Patterns, Prognostic Value, and Association with the Immune Microenvironment of EZH2 in Pan-Cancer and Hepatocellular Carcinoma
DOI: 10.12677/acm.2026.1641741, PDF,    科研立项经费支持
作者: 朱清杰：安徽医科大学第一附属医院全科医学科，安徽 合肥；黄裕涵, 马文文, 姜玮嘉, 孙国平*：安徽医科大学第一附属医院肿瘤内科，安徽 合肥
关键词: EZH2；泛癌；预后；肝癌；免疫浸润；EZH2； Pan-Cancer； Prognosis； Liver Hepatocellular Carcinoma； Immune Infiltration
摘要: 目的：基于多组学数据，解析EZH2在泛癌中的表达特征、预后价值及其与肝癌免疫微环境的关系。方法：整合多个公共数据库，分析EZH2的基因定位、组织表达、泛癌差异、临床相关性、基因变异及免疫浸润特征，并通过蛋白质互作网络与功能富集探讨其潜在机制。结果：EZH2在多种肿瘤中表达上调，与7种癌症分期、4种癌症分级呈正相关，为17种肿瘤的独立不良预后因素。在肝癌中，EZH2与免疫细胞浸润、免疫相关基因显著正相关，并可通过调控免疫、细胞周期等通路参与肿瘤进展。结论：EZH2是潜在的肿瘤诊断与预后生物标志物，且与肿瘤免疫微环境密切相关，为其作为免疫治疗新靶点提供了理论依据。
Abstract: Objective: To analyze the expression characteristics, prognostic value of EZH2 in pan-cancer and its relationship with the immune microenvironment of hepatocellular carcinoma based on multi-omics data. Methods: Multiple public databases were integrated to analyze the gene localization, tissue expression, pan-cancer differences, clinical correlation, gene variation and immune infiltration characteristics of EZH2. Its potential mechanism was explored via protein-protein interaction network and functional enrichment analysis. Results: EZH2 was upregulated in various tumors, positively correlated with tumor stage in 7 cancers and tumor grade in 4 cancers, and served as an independent adverse prognostic factor for 17 tumors. In hepatocellular carcinoma, EZH2 was significantly positively correlated with immune cell infiltration and immune-related genes, and participated in tumor progression by regulating immune response, cell cycle and other pathways. Conclusion: EZH2 is a potential biomarker for tumor diagnosis and prognosis, and is closely related to tumor immune microenvironment, which provides a theoretical basis for it as a new target for immunotherapy.
文章引用：朱清杰, 黄裕涵, 马文文, 姜玮嘉, 孙国平. EZH2在泛癌中的表达特征、预后价值及其与肝癌免疫微环境的关系[J]. 临床医学进展, 2026, 16(4): 4689-4706. https://doi.org/10.12677/acm.2026.1641741

参考文献

[1] Kaur, P., Shankar, E. and Gupta, S. (2024) EZH2-Mediated Development of Therapeutic Resistance in Cancer. Cancer Letters, 586, Article ID: 216706. [Google Scholar] [CrossRef] [PubMed]
[2] Wang, B., Liu, Y., Liao, Z., Wu, H., Zhang, B. and Zhang, L. (2023) EZH2 in Hepatocellular Carcinoma: Progression, Immunity, and Potential Targeting Therapies. Experimental Hematology & Oncology, 12, Article No. 52. [Google Scholar] [CrossRef] [PubMed]
[3] Yang, Y., Li, M., Ding, L., Zhang, Y., Liu, K., Liu, M., et al. (2024) EZH2 Promotes B-Cell Autoimmunity in Primary Sjogren’s Syndrome via METTL3-Mediated m6A Modification. Journal of Autoimmunity, 149, Article ID: 103341. [Google Scholar] [CrossRef] [PubMed]
[4] Guo, Y., Zhao, S. and Wang, G.G. (2021) Polycomb Gene Silencing Mechanisms: PRC2 Chromatin Targeting, H3K27me3 ‘Readout’, and Phase Separation-Based Compaction. Trends in Genetics, 37, 547-565. [Google Scholar] [CrossRef] [PubMed]
[5] Yu, J., Lee, C., Oksuz, O., Stafford, J.M. and Reinberg, D. (2019) PRC2 Is High Maintenance. Genes & Development, 33, 903-935. [Google Scholar] [CrossRef] [PubMed]
[6] Yang, Y., Zhang, Y., Cao, J., Su, Z., Li, F., Zhang, P., et al. (2023) FGFR4 and EZH2 Inhibitors Synergistically Induce Hepatocellular Carcinoma Apoptosis via Repressing YAP Signaling. Journal of Experimental & Clinical Cancer Research, 42, Article No. 96. [Google Scholar] [CrossRef] [PubMed]
[7] Zhang, L., Qu, J., Qi, Y., Duan, Y., Huang, Y., Zhou, Z., et al. (2022) EZH2 Engages TGFβ Signaling to Promote Breast Cancer Bone Metastasis via Integrin β1-FAK Activation. Nature Communications, 13, Article No. 2543. [Google Scholar] [CrossRef] [PubMed]
[8] Chen, J., Hong, J.H., Huang, Y., Liu, S., Yin, J., Deng, P., et al. (2023) EZH2 Mediated Metabolic Rewiring Promotes Tumor Growth Independently of Histone Methyltransferase Activity in Ovarian Cancer. Molecular Cancer, 22, Article No. 85. [Google Scholar] [CrossRef] [PubMed]
[9] Kim, K.H. and Roberts, C.W.M. (2016) Targeting EZH2 in Cancer. Nature Medicine, 22, 128-134. [Google Scholar] [CrossRef] [PubMed]
[10] Porazzi, P., Nason, S., Yang, Z., Carturan, A., Ghilardi, G., Guruprasad, P., et al. (2025) EZH1/EZH2 Inhibition Enhances Adoptive T Cell Immunotherapy against Multiple Cancer Models. Cancer Cell, 43, 537-551.e7. [Google Scholar] [CrossRef] [PubMed]
[11] Park, S.H., Fong, K., Mong, E., Martin, M.C., Schiltz, G.E. and Yu, J. (2021) Going Beyond Polycomb: EZH2 Functions in Prostate Cancer. Oncogene, 40, 5788-5798. [Google Scholar] [CrossRef] [PubMed]
[12] Guo, S., Li, X., Rohr, J., Wang, Y., Ma, S., Chen, P., et al. (2016) EZH2 Overexpression in Different Immunophenotypes of Breast Carcinoma and Association with Clinicopathologic Features. Diagnostic Pathology, 11, Article No. 41. [Google Scholar] [CrossRef] [PubMed]
[13] Sun, S., Yu, F., Xu, D., Zheng, H. and Li, M. (2022) EZH2, a Prominent Orchestrator of Genetic and Epigenetic Regulation of Solid Tumor Microenvironment and Immunotherapy. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1877, 188700. [Google Scholar] [CrossRef] [PubMed]
[14] Ernst, J., Kheradpour, P., Mikkelsen, T.S., Shoresh, N., Ward, L.D., Epstein, C.B., et al. (2011) Mapping and Analysis of Chromatin State Dynamics in Nine Human Cell Types. Nature, 473, 43-49. [Google Scholar] [CrossRef] [PubMed]
[15] Oki, S., Sone, K., Oda, K., Hamamoto, R., Ikemura, M., Maeda, D., et al. (2017) Oncogenic Histone Methyltransferase EZH2: A Novel Prognostic Marker with Therapeutic Potential in Endometrial Cancer. Oncotarget, 8, 40402-40411. [Google Scholar] [CrossRef] [PubMed]
[16] Venkadakrishnan, V.B., Presser, A.G., Singh, R., Booker, M.A., Traphagen, N.A., Weng, K., et al. (2024) Lineage-specific Canonical and Non-Canonical Activity of EZH2 in Advanced Prostate Cancer Subtypes. Nature Communications, 15, Article No. 6779. [Google Scholar] [CrossRef] [PubMed]
[17] Verma, S., Goyal, N., Goyal, S., Kaur, P. and Gupta, S. (2025) EZH2 Dysregulation and Its Oncogenic Role in Human Cancers. Cancers, 17, Article 3111. [Google Scholar] [CrossRef] 
[18] Mortezaee, K. (2025) EZH2 Regulatory Roles in Cancer Immunity and Immunotherapy. Pathology—Research and Practice, 270, Article ID: 155992. [Google Scholar] [CrossRef] [PubMed]
[19] Guo, H., Vuille, J.A., Wittner, B.S., Lachtara, E.M., Hou, Y., Lin, M., et al. (2023) DNA Hypomethylation Silences Anti-Tumor Immune Genes in Early Prostate Cancer and CTCs. Cell, 186, 2765-2782.e28. [Google Scholar] [CrossRef] [PubMed]
[20] Zhou, J., Liu, M., Sun, H., Feng, Y., Xu, L., Chan, A.W.H., et al. (2018) Hepatoma-Intrinsic CCRK Inhibition Diminishes Myeloid-Derived Suppressor Cell Immunosuppression and Enhances Immune-Checkpoint Blockade Efficacy. Gut, 67, 931-944. [Google Scholar] [CrossRef] [PubMed]

为你推荐